PCV2 virus is the causal agent of PCV Associated Disease (PCVAD), an economically important disease in the global swine sector. PCV2 epidemics can cause clinical disease, however nowadays the majority of PCV2 infections are endemic and often with sub-clinical symptoms only.PCV2-subclinical infections (SI) are more difficult to diagnose, with sub-optimal performance as the most important factor causing economic loss. The presence of PCV2 virus in pigs is a risk factor for economic damage. In the modern pork producing industry risk factors need to be identified, monitored and if possible controlled. A PCV2 monitoring program can identify both clinical and subclinical PCV2 related problems. With the help of a monitoring program the uniformity of PCV2 immune status in a batch of pigs can be investigated, as well as the moment when field infection occurred and if the chosen vaccination timing is optimal for the conditions prevailing on the farm.
Dr. Alex Eggen will explain how to get the most out of your PCV2 vaccination and control program by using both the PCV2 ELISA and the PCV2 qPCR method for PCV2 monitoring purposes. He will provide detailed information as to what kind of information can be distilled out of a serological investigation. He will illustrate these findings with data from the field and he will show how optimal PCV2 protection can be achieved by monitoring for PCV2 virus and antibodies.
This webinar will broadcast at:
- 9:00 AM CET (Amsterdam)
- 3:00 PM ICT (Bangkok)
WHAT YOU’LL LEARN:
- Why monitoring PCV2 dynamics is important from a financial perspective, and how to set up such a monitoring program
- How to use ELISA to check for PCV2 related immunity
- How to use ELISA to check for uniformity and vaccination timing
- How to use the qPCR to check for PCV2 virus control
This webinar is sponsored by Biochek and presented by WATT Global Media.
Speaker Info:
Dr. Alex Eggen, Consultant, AEVC
Dr. Alex Eggen started his own veterinary consultancy (AEVC) office after a term of 28 years with Intervet International (now part of Merck/MSD AH) at the corporate Headquarters in Boxmeer, the Netherlands. He grew up in the Netherlands, graduated from Utrecht University and worked in several veterinary practices and for FAO in Africa before joining the pharmaceutical industry. During his time at Intervet International the PCV2 vaccines were developed, tested in the field and introduced world-wide. He left the company at the level of Technical Director Swine products for Global MSD AH. Since then he is active in advising different companies in the field of optimal use of vaccines.
Dr. Guillermo Zavala is the founder of Avian Health International. Dr Zavala holds a DVM and a specialty in poultry production from the University of Mexico; a Master of Science, a Master of Avian Medicine, and a PhD in medical microbiology from the University of Georgia. He has worked in broiler and breeding companies, vaccine companies, one diagnostic laboratory, two academic institutions and as Adjunct Professor at the Department of Population Health, University of Georgia. His field of research is in applied virology (CIAV, IBDV, tumor viruses, ILT, enteric viruses and fowl adenovirus). He has 32 publications in peer-reviewed journals.